{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:26:48Z","timestamp":1791163608643,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,9,2]],"date-time":"2005-09-02T00:00:00Z","timestamp":1125619200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the safety and efficacy of B cell depletion treatment of patients with active primary Sj\u00f6gren's syndrome of short duration (early primary SS) and patients with primary SS and mucosa\u2010associated lymphoid tissue (MALT)\u2013type lymphoma (MALT\/primary SS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifteen patients with primary SS were included in this phase II trial. Inclusion criteria for the early primary SS group were B cell hyperactivity (IgG &gt;15 gm\/liter), presence of autoantibodies (IgM rheumatoid factor, anti\u2010SSA\/SSB), and short disease duration (&lt;4 years). Inclusion criteria for the MALT\/primary SS group were primary SS and an associated MALT\u2010type lymphoma (Ann Arbor stage IE) localized in the parotid gland. Patients were treated with 4 infusions of rituximab (375 mg\/m<jats:sup>2<\/jats:sup>) given weekly after pretreatment with prednisone (25 mg) and clemastine. Patients were evaluated, using immunologic, salivary\/lacrimal function, and subjective parameters, at baseline and at 5 and 12 weeks after the first infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant improvement of subjective symptoms and an increase in salivary gland function was observed in patients with residual salivary gland function. Immunologic analysis showed a rapid decrease of peripheral B cells and stable levels of IgG. Human antichimeric antibodies (HACAs) developed in 4 of 15 patients (27%), all with early primary SS. Three of these patients developed a serum sickness\u2013like disorder. Of the 7 patients with MALT\/primary SS, complete remission was achieved in 3, and disease was stable in 3 and progressive in 1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Findings of this phase II study suggest that rituximab is effective in the treatment of primary SS. The high incidence of HACAs and associated side effects observed in this study needs further evaluation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.21260","type":"journal-article","created":{"date-parts":[[2005,9,2]],"date-time":"2005-09-02T15:49:23Z","timestamp":1125676163000},"page":"2740-2750","source":"Crossref","is-referenced-by-count":426,"title":["Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: An open\u2010label phase II study"],"prefix":"10.1002","volume":"52","author":[{"given":"J.","family":"Pijpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. W.","family":"van Imhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. K. L.","family":"Spijkervet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L. N.","family":"Roodenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vissink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. G. M.","family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,9,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/030097400447525"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.8.465"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10947"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2004.04.006"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_6_11_2","first-page":"206","article-title":"Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjogren's syndrome","volume":"30","author":"Pijpe J","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.554"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_6_14_2","series-title":"Clinical reviews in allergy","first-page":"289","author":"Aalberse RC","year":"1983"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.2.137"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(76)90229-2"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1969.00990020012003"},{"key":"e_1_2_6_18_2","first-page":"924","article-title":"Oral and ocular manifestations in Sjogren's syndrome","volume":"29","author":"Kalk WW","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(94)00125-O"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.5.291"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/030097400750001761"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029694"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030684"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-200202000-00019"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11109"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh248"},{"key":"e_1_2_6_29_2","first-page":"143","article-title":"Outcome measures for Sjogren's syndrome, April 10\u201011, 2003, Bethesda, Maryland, USA","volume":"32","author":"Pillemer SR","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(92)90005-X"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<908::AID-ANR24>3.0.CO;2-K"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200405000-00013"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb18379.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.1999.tb00077.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg488"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10127"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10541"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.883"},{"key":"e_1_2_6_41_2","first-page":"149","article-title":"Prednisone and piroxicam for treatment of primary Sjogren's syndrome","volume":"11","author":"Fox PC","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.21260","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.21260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:18:26Z","timestamp":1696972706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.21260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1002\/art.21260"],"URL":"https:\/\/doi.org\/10.1002\/art.21260","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}